IWP 4

Research use only, not for human use.

IWP-4 is a potent Wnt inhibitor.

IWP-4 is a novel potent inhibitor of Wnt/β-catenin signaling.

IWP-4 is a small molecule Wnt inhibitor with an IC50 of 25 nM. IWP-4 induces the expression of cardiac markers, including cardiac troponin I (CTNI) and cardiac myosin heavy chain bright cells (MYHhi +). IWP-4 also results in the appearance of beating foci (0.44±0.10 SEM beats per second), which is absent in all cultures not receiving IWP-4. Further, flow cytometric analysis shows that there are significantly more MYHlo + cells in IWP-4 treated cultures (P<0.0002) compare with untreated cultures at day 16, being 17.0±1.3 SD% and 5.4±1.4 SD%, respectively. Quantification of NKX2-5 protein expression shows that 63% (481/817) of IWP-4 treated cells display nuclear NKX2-5 expression. Mesenchymal precursor cells (MPCs) treated with IWP-4 show no significant changes in the expression of AXIN2, CTNNB1 and GSK3B as compare to osteogenic medium alone on day 7, but MPCs treated with IWP-4 express elevates levels of DKK1 and GSK3β on day 21.IWP-4 also causes a significant down regulation of SPARC and COL1A1.

——

IWP4 | IWP 4 | IWP-4

Neuroscience

GluR

Wnt

——

——

686772-17-8

496.6

C23H20N4O3S3

>98% (HPLC)

DMSO : 5 mg/mL. 10.07 mM;

COc1ccccc1-n1c(SCC(=O)Nc2nc3ccc(C)cc3s2)nc2CCSc2c1=O

N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-3-(2-methoxyphenyl)-4-oxothieno[3,2-d]pyrimidin-2-yl)thio]-acetamide

(-20℃)

With Ice Pack

≥ 2 years